52-Week Open-Label Safety and Tolerability Trial of Centanafadine Sustained Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Authors
Category Primary study
ConferenceNeuroscience Education Institute Congress, NEI 2023
Year 2024
This article has no abstract
Epistemonikos ID: 2ec5e7eaf669a8075876776a9ae78d6a91456b4b
First added on: Apr 19, 2025